NCT01489293

Brief Summary

The purpose of this study is to analyze the expression and activity of inhibitory molecules on eosinophils obtained from allergic subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 7, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 9, 2011

Completed
5 months until next milestone

Study Start

First participant enrolled

May 1, 2012

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2013

Completed
Last Updated

March 22, 2018

Status Verified

March 1, 2018

Enrollment Period

1.7 years

First QC Date

December 7, 2011

Last Update Submit

March 21, 2018

Conditions

AtopyAtopic DermatitisAsthmaAllergic RhinitisFood Allergy

Outcome Measures

Primary Outcomes (1)

  • Expression of surface molecules on eosinophils as assessed by flow cytometry

    Blood samples from donors will be stained and evaluated by flow cytomtery

    December 2013

Study Arms (2)

atopic subjects

Patients with one atopic disease or more (atopic dermatitis,rhinitis, asthma, food allergy)

non-atopic subjects

Control group without atopic diseases.

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

allergy clinic

You may qualify if:

  • age 20-60 years
  • a physician-diagnosed atopic disease

You may not qualify if:

  • atopic disease not active
  • steroid treatment
  • active non-atopic inflammatory disease, including infections
  • pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Meir Medical Center. Unit of Allergy and Clinical Immunology

Kfar Saba, Israel

Location

Biospecimen

Retention: SAMPLES WITH DNA

whole blood

MeSH Terms

Conditions

Dermatitis, AtopicAsthmaRhinitis, AllergicFood Hypersensitivity

Condition Hierarchy (Ancestors)

Skin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateHypersensitivityImmune System DiseasesBronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityRhinitisNose DiseasesOtorhinolaryngologic Diseases

Study Officials

  • Alon Y Hershko, MD, PhD

    Meir Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 7, 2011

First Posted

December 9, 2011

Study Start

May 1, 2012

Primary Completion

December 31, 2013

Study Completion

December 31, 2013

Last Updated

March 22, 2018

Record last verified: 2018-03

Locations

IL(1)